Susan Raschal, DO
Allergy & Immunology · Chattanooga, TNNPI 1063451813
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by AstraZeneca at 58.0% of the total. Reporting peaked in 2022 at $11,450 and has fallen 70.6% since, to $3,370 in 2025.
Across 758 payments — averaging $52.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$23K
- Amgen$3K
- GSK$2K
- Sanofi$2K
- CSL Behring$2K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $7K from 35 others
What the payments were for
- Consulting fees$1,5764%
- Speaking & faculty fees$20,85052%
- Travel & lodging$9802%
- Food & beverage$16,55141%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,989 in reported general payments places this provider in the 80th percentile of 79 allergy & immunology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 76 | $203,549 |
| Dupixent SyringeDupilumab | 24 | $131,911 |
| Dupixent PenDupilumab | 27 | $108,952 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 101 | $67,801 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $65,852 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $13,677 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $10,219 |
| Spiriva RespimatTiotropium Bromide | 14 | $9,287 |
| Epinephrine | 42 | $8,694 |
| XhanceFluticasone Propionate | 11 | $8,002 |
| Arnuity ElliptaFluticasone Furoate | 28 | $7,894 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $6,325 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,636 |
| Pulmicort FlexhalerBudesonide | 19 | $5,129 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $4,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,824 | $90,290161 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $23,194 | $86,608167 claims |
| Boehringer IngelheimSpiriva Respimat | $299 | $9,28714 claims |
| Hikma Pharmaceuticals USAEpinephrine | $29 | $8,69442 claims |
| Optinose US, Inc.Xhance | $936 | $8,00211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 79 allergy & immunology providers in Tennessee.
Other allergy & immunology in Chattanooga
- Marc CromieChattanooga$106K
- Todd LevinChattanooga$64K
- Jennifer PatelChattanooga$12K
- Lee PerryChattanooga$10K
- Joseph WisniewskiChattanooga$6K
- David ChaffinChattanooga$5K
- Jessica van MasonChattanooga$5K
- Taylor AtchleyChattanooga$4K
- Michael HollieChattanooga$3K
- Paul CarterChattanooga$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.